Did You Know...
...that power steering was invented by independent inventor Francis W. Davis? As chief engineer in the 1920s of the truck division of the Pierce Arrow Motor Car Company, he saw how hard it was to steer heavy vehicles. So that he would be able to keep the profits from his future invention, Davis left his job, rented a small engineering shop in Waltham, Mass., and developed a hydraulic power steering system that led to power steering.
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Number | Title | Issue Date |
| 8153800 | Macrocyclic inhibitors of hepatitis C virus Inhibitors of HCV replication of formula (I) and the N-oxides, salts, and stereoisomers, wherein each dashed line represents an optional double bond; X is N, CH and where X bears a double bond i... | 04/10/2012 |
| 7514557 | Process for preparing acyclic HCV protease inhibitors Disclosed are highly convergent processes for preparing compounds of formula (I), which compounds are potent active agents for the treatment of hepatitis C virus (HCV) infection: The disclosed processes use SNAr-ty... | 04/07/2009 |
| 7186840 | Quinoline derivatives as anti-inflammatory agents This invention relates to compounds, which are generally anti-inflammatory and analgesic compounds, and which are represented by Formula I: wherein A is a CH2, CH(OH), C(O), C═NOR4, NR | 03/06/2007 |
| 7147704 | Pigment dispersing agent, pigment composition and pigment dispersion A pigment dispersing agent wherein a quinophthalone structure is bonded to a triazine structure through an arylene group or a heteroaromatic ring and a basic functional group is bonded to triazine ring through a connecting group which pigment dispersing agent improv... | 12/12/2006 |
| 7091261 | Yellow hue compound and aqueous ink for ink-jet recording system using the same Aqueous ink for ink-jet recording which contains at least a water-insoluble coloring matter, water and a resin as main components and which takes the form of an emulsion, in which the coloring matter is at least one yellow hue coloring matter selected from the group... | 08/15/2006 |
| 6964966 | Generation triple-targeting, chiral, broad-spectrum antimicrobial 7-substituted piperidino-quinolone carboxylic acid derivatives, their preparation, compositions and use as medicaments This invention relates to new generation triple-targeting, chiral, broad-spectrum antimicrobial 7-substituted piperidino-quinolone carboxylic acid derivatives, to their optical isomers, diastereomers or enantiomers, as well as pharmaceutically acceptable salts, hydr... | 11/15/2005 |
| 6878722 | Substituted cycloalkyl P1′ hepatitis C virus inhibitors The present invention relates to tripeptide compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. In particular, the present invention provides novel tripeptide analogs, pharmaceutical compositions containing such analogs and me... | 04/12/2005 |
| 6878713 | Generation triple-targeting, chiral, broad-spectrum antimicrobial 7-substituted piperidino-quinolone carboxylic acid derivatives, their preparation, compositions and use as medicaments This invention relates to new generation triple-targeting, chiral, broad-spectrum antimicrobial 7-substituted piperidino-quinolone carboxylic acid derivatives, to their optical isomers, diastereomers or enantiomers, as well as pharmaceutically acceptable salts, hydr... | 04/12/2005 |
| 6869964 | Heterocyclicsulfonamide hepatitis C virus inhibitors The present invention relates to tripeptide compounds, compositions containing such compounds and methods for using such compounds for the treatment of hepatitis C virus (HCV) infection. In particular, the present invention provides novel tripeptide analogs, pharmac... | 03/22/2005 |
| 6849116 | Quinophthalone-derivative based crystallization modifiers Quinophthalone derivatives have the general formula I where R1, R2, R3 and R5 are independently hydrogen, halogen or C1-C4-alkyl; ... | 02/01/2005 |
| 6844439 | Process for the preparation of imidazole compounds A process for the preparation of 4-(3-chlorophenyl)-6-[(4-chlorophenyl)hydroxy(1-methyl-1H-imidazol-5-yl)methyl]-1-methyl-2(1H)-quinolinone which comprises reacting 6-(4-chlorobenzoyl)-4-(3-chlorophenyl)-1-methyl-2(1H)-quinolinone with a C6-8alkyllithium ... | 01/18/2005 |
| 6844357 | Substituted quinolin-2-one derivatives useful as antiproliferative agents The present invention relates to compounds of formulas 1 and 2 wherein R1, R2, R4, R5, R6, R7, R8, R10 and Z are as defined herein... | 01/18/2005 |
| 6833455 | Bridged perinones/quinophthalones Disclosed herein are bridged perinones/quinophthalones of the general formula (I) or tautomeric forms thereof where X1, X2, Ar1 Ar2 and B are as described herein and are particularly characterized... | 12/21/2004 |
| 6806276 | 2-oxoquinoline compounds and pharmaceutical uses thereof A 2-oxoquinoline compound or its pharmaceutically acceptable salt of general formula [I]: (wherein each symbol in the formula is as determined in the description), and its pharmaceutical use. The compound [I] of the pr... | 10/19/2004 |
| 6762194 | Quinolinone derivatives Organic compounds having the formulas I and II are provided where the variables have the values described herein. Pharmaceutical formulations include the organic compounds or pharmaceutically acceptable salts thereof and... | 07/13/2004 |
| 6509352 | 2-oxoquinoline compounds and medicinal uses thereof A 2-oxoquinoline compound or its pharmaceutically acceptable salt of general formula [I]: ##STR1## (wherein each symbol in the formula is as determined in the description), and its pharmaceutical use. The compound [I] of the present invention and its phar... | 01/21/2003 |
| 6486143 | 6-amino- or 6-hydrazino-sulphonyl-3-quinolynyl-phosphonic acid compounds The invention relates to a compound of formula (I): ##STR1## wherein: R1 represents halogen or a group CF3, R2 represents hydrogen or alkyl or cycloalkyl, R3 is as defined in the description, R4 and R5 | 11/26/2002 |
| 6448254 | Substituted amides, their production and their use Amides of the general formula I ##STR1## and their tautomeric and isomeric forms, possible enantiomeric and diastereomeric forms, as well as possible physiologically tolerable salts, in which the variables have the following meanings: R1 [sic] can be C | 09/10/2002 |
| 6440995 | Quinolin-4-yl derivatives Phenyl substituted quinolin 4-yl derivatives and pharmaceutical compositions with activity as NMDA-receptor subtype selective blockers. The compounds of the invention modulate neuronal activity and plasticity.... | 08/27/2002 |
| 6420555 | Imidazolyl derivatives ##STR1## The present invention is directed to imidazolyl derivatives of formula (I), wherein the variables are defined in the specification, which are useful as prenyl transferase inhibitors.... | 07/16/2002 |
| 6329389 | Amine compounds, their production and use The present invention provides a compound of the formula: ##STR1## wherein Ar represents an aromatic group which may be substituted; X represents methylene, S, SO, SO2 or CO; Y represents a spacer having a main chain of 2 to 5 atoms; n represents an inte... | 12/11/2001 |
| 6274728 | Soluble chromophores having improved solubilizing groups Compounds of formula A(B)x (I), wherein x is an integer from 1 to 8, A is the radical of a chromophore of the quinacridone, anthraquinone, perylene, indigo, quinophthalone, indanthrone, isoindolinone, isoindoline, dioxazine, azo, phthalocyanine or ... | 08/14/2001 |
| 6172084 | Quinoline-indole antimicrobial agents, uses and compositions related thereto The present invention provides methods and pharmaceutical preparations that inhibit the growth of bacterial microorganisms. Additionally, the present invention provides methods and pharmaceutical preparations that kill bacterial microorganisms.... | 01/09/2001 |
| 6169096 | Farnesyl protein transferase inhibiting (imidazol-5-yl)methyl-2-quinolinone derivatives This invention comprises the novel compounds of formula (I) ##STR1## wherein the dotted line represents an optional bond; X is oxygen or sulfur; R1 is hydrogen, C1-12 alkyl, Ar1, Ar2 C1-6 alkyl, quino... | 01/02/2001 |
| 6143895 | Quinoline derivatives and quinoline combinatorial libraries The present invention relates to novel tetrahydro-quinoline compounds of the following formula, libraries containing such compounds, and to the generation of such combinatorial libraries composed of such compounds: ##STR1## wherein R1, R | 11/07/2000 |
| 6121452 | Process for the preparation of quinophthalones The present invention relates to a process for preparing compounds of formula (I) ##STR1## wherein A completes an unsubstituted or substituted heteroaromatic ring and B completes an unsubstituted or substituted aromatic ring, by reacting a heter... | 09/19/2000 |
| 6080757 | Antibiotic quinolones and derivatives A compound of the formula I ##STR1## or a pharmaceutically acceptable salt or hydrate thereof, wherein X, Y, Z and R1 to R7 are as defined herein, are inhibitors of H. pylori and therefore of use in the treatment and prevention ... | 06/27/2000 |
| 6051360 | Dyestuffs and resin compositions Dyestuffs represented by the below-described formula (1), that is, dyestuffs formed of a chromophoric nucleus and a bisphenol introduced therein have excellent solubility in solvents and binder resins, and can provide color filters having excellent transm... | 04/18/2000 |
| 6037350 | Farnesyl protein transferase inhibiting (imidazol-5-yl)methyl-2-quionlinone derivatives This invention comprises the novel compounds of formula (I) ##STR1## wherein the dotted line represents an optional bond; X is oxygen or sulfur; R1 is hydrogen, C1-12 alkyl, Ar1, Ar2 C1-6 alkyl, ... | 03/14/2000 |
| 5968952 | Farnesyl transferase inhibiting 2-quinolone derivatives The present invention is concerned with compounds of formula (I), ##STR1## the stereoisomeric forms thereof and the pharmaceutically acceptable acid or base addition salts thereof, wherein the dotted line represents an optional bond; X is oxygen or s... | 10/19/1999 |
| 5929087 | Decahydroquinoline-based anti-cholinergic agents Compounds of formula I or formula II: ##STR1## wherein R, J, and Q have any of the values defined in the specification, and their pharmaceutically acceptable salts and related radiopharmaceuticals, have anticholinergic activity, and are useful for ... | 07/27/1999 |
| 5852043 | HIV protease inhibitors HIV protease inhibitors, obtainable by chemical synthesis, inhibit or block the biological activity of the HIV protease enzyme, causing the replication of the HIV virus to terminate. These compounds, as well as pharmaceutical compositions that contain the... | 12/22/1998 |
| 5849756 | Pharmaceutical composition and method for modulating the immune reaction Pharmaceutical compositions for the modulation of the immune reaction of warm blooded animals that are derivatives of the 2-oxindole-3-acetic acid or the 2-oxo-1,2,3,4-tetrahydroquinoline-4-carboxylic acid are described, and whereby the derivatives can op... | 12/15/1998 |
| 5780627 | Fluorescent dioxazine pigments Compounds of formula A(B)x, (I), wherein x is an integer from 1 to 4, A is the radical of a chromophore of the quinacridone, anthraquinone, perylene, indigo, quinophthalone, isoindolinone, isoindoline, dioxa... | 07/14/1998 |
| 5750599 | Quinophthalone compounds and polarizing films using same Novel quinophthalone compounds, which are represented by the following formula (1): ##STR1## R1 -R5 each independently represents a hydrogen or halogen atom or a hydroxy, linear or branched alkyl, substituted or unsubstituted ... | 05/12/1998 |
| 5731321 | Endothelin receptor antagonists Novel compounds of the formula I ##STR1## in which --Y--Z--, R1, R2, R3, R4 and R5 have the meanings as stated in the specification, and their salts show endothelin receptor antagonist properties... | 03/24/1998 |
| 5695684 | Mesomorphic compound, liquid crystal composition containing the compound, liquid crystal device using the composition, liquid crystal apparatus and display method A mesomorphic compound represented by a formula (I) containing a quinoline-2,6-diyl skeleton is suitable as a component for a liquid crystal composition providing improved response characteristics and a high contrast. A liquid crystal device is constitute... | 12/09/1997 |
| 5691322 | Quinoline and pyridine anchors for HMG-CoA reductase inhibitors Compounds which are useful as inhibitors of cholesterol biosynthesis and thus as hypocholesterolemic agents are provided which have a quinoline or a pyridine anchor attached by means of a linker to a binding domain sidechain, which compounds inhibit the e... | 11/25/1997 |
| 5659039 | Quinophthalone compounds Novel quinophthalone compounds, which are represented by the following formula (1): ##STR1## R1 -R5 each independently represents a hydrogen or halogen atom or a hydroxy, linear or branched alkyl, substituted or unsubstituted ... | 08/19/1997 |
| 5571822 | Antitumor compounds A method of inhibiting tumor-cell growth in a mammalian subject, by administering a therapeutically effective amount of a selected 2-phenyl-4-quinolone compound. The selected compound shows unexpectely high activity against a variety of solid tumor cells.... | 11/05/1996 |
